Equibles does not estimate personal net worth.
Get an email with a short summary when Prestige Consumer Healthcare Inc. publishes a filing, an earnings call transcript or a press release.
Get PBH alertsChris Sacco is recorded as CFO at Prestige Consumer Healthcare Inc. (PBH). Chris Sacco has spoken on 5 earnings calls and 4 other investor events across 1 company, most recently for Prestige Consumer Healthcare Inc. on August 12, 2026. Prestige Consumer Healthcare Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Prestige Consumer Healthcare Inc. includes Ronald M. Lombardi (CEO and Board Member), Christine Sacco (CFO and COO), William C. P’Pool (General Counsel) and 7 others.
“So Prestige has been executing a three-pillar strategy for some time. Phil and I have been with the company about 10 years, and the strategies remain the same. Of course, we've been through a lot of volatility, all of us, right, macro environment.”
“So we've come to this conference a number of years, and in the last few years we get a lot of questions around M&A. We're an inquisitive company, and, you know, why are you out of the market?”
“Let's turn to slide 11 and review our first quarter Fiscal 27 financial results. As a reminder, the information in today's presentation includes certain non-GAAP information that is reconciled to the closest GAAP measure in our earnings release.”
“So we have not seen a lot of variability. When we think about consumption in our channels, it's been fairly consistent. We do hear some folks talk about, it seems like there could be a bubble in certain channels out there.”
“Let me first walk everyone through the highlights. We're acquiring a portfolio of brand headlined by Breedwright. The purchase price is $1,045,000,000 or $900,000,000 net of anticipated tax benefits.”
Drug Manufacturers - Specialty & Generic · Healthcare
CFO
